Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06313359 · ClinicalTrials.gov registry record

Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.

A clinical trial of Peripheral Neuropathy Due to Chemotherapy, sponsored by Texas Woman's University.

Recruiting
Registry status
40
Enrollment target
1
Study location

NCT06313359 is a study of Peripheral Neuropathy Due to Chemotherapy that is actively recruiting participants, run by Texas Woman's University. The registered enrollment target is 40 participants, below the 54-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06313359, a study of Peripheral Neuropathy Due to Chemotherapy, is actively recruiting participants, sponsored by Texas Woman's University.

RECRUITING
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to examine the impact of peripheral neuropathy on fall risk and quality of life in people who had cancer and neuropathy from cancer treatments. The investigators are interested to find out if the participant have any difficulty with thinking, feeling, balancing, or moving around that will contribute to risk for falls or quality of life. Investigators are also interested to see if the participants have any difficulty with doing two activities at the same time, such as walking and texting.

Study Locations (1)

Texas

  • Texas Woman's University - Dallas

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-03-30
Est. Completion 2026-06-30

Sponsor

Texas Woman's University

51 total trials

What the Registry Record Tells You About NCT06313359

The ClinicalTrials.gov registry entry for NCT06313359 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (26% lower). The listed sponsor is Texas Woman's University, which has 51 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 0 interventions.

NCT06313359 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06313359 about?

NCT06313359 is a clinical study titled "Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.". The purpose of this research is to examine the impact of peripheral neuropathy on fall risk and quality of life in people who had cancer and neuropathy from cancer treatments. The investigators are interested to find out if the participant have any difficulty with thinking, feeling, balancing, or mo...

What is the current status of trial NCT06313359?

This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2024-03-30. Estimated completion is 2026-06-30.

What conditions does trial NCT06313359 study?

This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy.

Who is sponsoring clinical trial NCT06313359?

This trial is sponsored by Texas Woman's University, which has 51 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06313359 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Neuropathy Due to Chemotherapy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.